{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:53:49Z","timestamp":1790502829016,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773016"],"award-info":[{"award-number":["81773016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21976155"],"award-info":[{"award-number":["21976155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31471297"],"award-info":[{"award-number":["31471297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41423-020-0444-5","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T07:02:49Z","timestamp":1591772569000},"page":"1278-1289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12 signaling pathway"],"prefix":"10.1038","volume":"18","author":[{"given":"Bo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4871-8789","authenticated-orcid":false,"given":"Hanwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"H\u00e9roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Ming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"444_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2015.113","volume":"13","author":"F Rollini","year":"2016","unstructured":"Rollini, F., Franchi, F. & Angiolillo, D. J. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat. Rev. Cardiol. 13, 11\u201327 (2016).","journal-title":"Nat. Rev. Cardiol."},{"key":"444_CR2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.110.985325","volume":"123","author":"MA Gaglia Jr.","year":"2011","unstructured":"Gaglia, M. A. Jr. & Waksman, R. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation 123, 451\u2013456 (2011).","journal-title":"Circulation"},{"key":"444_CR3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045\u20131057 (2009).","journal-title":"N. Engl. J. Med."},{"key":"444_CR4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","volume":"60","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos, D. et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J. Am. Coll. Cardiol. 60, 193\u2013199 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"444_CR5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi, M. et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37, 267\u2013315 (2016).","journal-title":"Eur. Heart J."},{"key":"444_CR6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/gutjnl-2015-311110","volume":"65","author":"AM Veitch","year":"2016","unstructured":"Veitch, A. M. et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Gut 65, 374\u2013389 (2016).","journal-title":"Gut"},{"key":"444_CR7","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.jacc.2012.07.021","volume":"60","author":"C Varenhorst","year":"2012","unstructured":"Varenhorst, C. et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J. Am. Coll. Cardiol. 60, 1623\u20131630 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"444_CR8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/09537104.2013.842965","volume":"25","author":"RF Storey","year":"2014","unstructured":"Storey, R. F. et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 25, 517\u2013525 (2014).","journal-title":"Platelets"},{"key":"444_CR9","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jcin.2017.05.064","volume":"10","author":"HS Jeong","year":"2017","unstructured":"Jeong, H. S. et al. Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with non-ST-segment elevation acute coronary syndrome requiring coronary stenting: a prospective, randomized, crossover trial. JACC Cardiovasc. Interv. 10, 1646\u20131658 (2017).","journal-title":"JACC Cardiovasc. Interv."},{"key":"444_CR10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10557-016-6701-2","volume":"30","author":"Y Birnbaum","year":"2016","unstructured":"Birnbaum, Y., Birnbaum, G. D., Birnbaum, I., Nylander, S. & Ye, Y. Ticagrelor and rosuvastatin have additive cardioprotective effects via adenosine. Cardiovasc. Drugs Ther. 30, 539\u2013550 (2016).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"444_CR11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo, H., Callaway, J. B. & Ting, J. P. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677\u2013687 (2015).","journal-title":"Nat. Med."},{"key":"444_CR12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","volume":"157","author":"M Lamkanfi","year":"2014","unstructured":"Lamkanfi, M. & Dixit, V. M. Mechanisms and functions of inflammasomes. Cell 157, 1013\u20131022 (2014).","journal-title":"Cell"},{"key":"444_CR13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"444_CR14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"K Schroder","year":"2010","unstructured":"Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821\u2013832 (2010).","journal-title":"Cell"},{"key":"444_CR15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","volume":"10","author":"GY Chen","year":"2010","unstructured":"Chen, G. Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826\u2013837 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"444_CR16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molcel.2014.03.029","volume":"54","author":"GR Robbins","year":"2014","unstructured":"Robbins, G. R., Wen, H. & Ting, J. P. Inflammasomes and metabolic disorders: old genes in modern diseases. Mol. Cell 54, 297\u2013308 (2014).","journal-title":"Mol. Cell"},{"key":"444_CR17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","volume":"15","author":"S Toldo","year":"2016","unstructured":"Toldo, S. & Abbate, A. The NLRP3 inflammasome in acute myocardial infarction. Nat. Rev. Cardiol. 15, 203\u2013214 (2016).","journal-title":"Nat. Rev. Cardiol."},{"key":"444_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0296-z","author":"X Unamuno","year":"2019","unstructured":"Unamuno, X. et al. NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling. Cell. Mol. Immunol. https:\/\/doi.org\/10.1038\/s41423-019-0296-z (2019).","journal-title":"Cell. Mol. Immunol."},{"key":"444_CR19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248\u2013255 (2015).","journal-title":"Nat. Med."},{"key":"444_CR20","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang, H. et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 214, 3219\u20133238 (2017).","journal-title":"J. Exp. Med."},{"key":"444_CR21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","volume":"160","author":"Y Yan","year":"2015","unstructured":"Yan, Y. et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160, 62\u201373 (2015).","journal-title":"Cell"},{"key":"444_CR22","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","volume":"45","author":"C Guo","year":"2016","unstructured":"Guo, C. et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45, 802\u2013816 (2016).","journal-title":"Immunity"},{"key":"444_CR23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.it.2014.02.007","volume":"35","author":"T Horng","year":"2014","unstructured":"Horng, T. Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome. Trends Immunol. 35, 253\u2013261 (2014).","journal-title":"Trends Immunol."},{"key":"444_CR24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1146\/annurev-immunol-031210-101405","volume":"29","author":"BK Davis","year":"2011","unstructured":"Davis, B. K., Wen, H. & Ting, J. P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 29, 707\u2013735 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"444_CR25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature07725","volume":"458","author":"V Hornung","year":"2009","unstructured":"Hornung, V. et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514\u2013518 (2009).","journal-title":"Nature"},{"key":"444_CR26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coi.2015.01.010","volume":"32","author":"RE Vance","year":"2015","unstructured":"Vance, R. E. The NAIP\/NLRC4 inflammasomes. Curr. Opin. Immunol. 32, 84\u201389 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"444_CR27","doi-asserted-by":"crossref","first-page":"ra55","DOI":"10.1126\/scisignal.2000588","volume":"3","author":"M Kronlage","year":"2010","unstructured":"Kronlage, M. et al. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci. Signal. 3, ra55 (2010).","journal-title":"Sci. Signal."},{"key":"444_CR28","first-page":"e81","volume":"32","author":"D Li","year":"2012","unstructured":"Li, D. et al. Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 32, e81\u2013e89 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"444_CR29","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1074\/jbc.273.4.2024","volume":"273","author":"JL Daniel","year":"1998","unstructured":"Daniel, J. L. et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem. 273, 2024\u20132029 (1998).","journal-title":"J. Biol. Chem."},{"key":"444_CR30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","volume":"409","author":"G Hollopeter","year":"2001","unstructured":"Hollopeter, G. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409, 202\u2013207 (2001).","journal-title":"Nature"},{"key":"444_CR31","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI12242","volume":"107","author":"CJ Foster","year":"2001","unstructured":"Foster, C. J. et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J. Clin. Investig. 107, 1591\u20131598 (2001).","journal-title":"J. Clin. Investig."},{"key":"444_CR32","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2016-03-707844","volume":"128","author":"R Aungraheeta","year":"2016","unstructured":"Aungraheeta, R. et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood 128, 2717\u20132728 (2016).","journal-title":"Blood"},{"key":"444_CR33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature11588","volume":"492","author":"GS Lee","year":"2012","unstructured":"Lee, G. S. et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492, 123\u2013127 (2012).","journal-title":"Nature"},{"key":"444_CR34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","volume":"183","author":"FG Bauernfeind","year":"2009","unstructured":"Bauernfeind, F. G. et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787\u2013791 (2009).","journal-title":"J. Immunol."},{"key":"444_CR35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.molcel.2012.11.009","volume":"49","author":"BF Py","year":"2013","unstructured":"Py, B. F., Kim, M. S., Vakifahmetoglu-Norberg, H. & Yuan, J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 49, 331\u2013338 (2013).","journal-title":"Mol. Cell"},{"key":"444_CR36","doi-asserted-by":"crossref","first-page":"36617","DOI":"10.1074\/jbc.M112.407130","volume":"287","author":"C Juliana","year":"2012","unstructured":"Juliana, C. et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J. Biol. Chem. 287, 36617\u201336622 (2012).","journal-title":"J. Biol. Chem."},{"key":"444_CR37","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.cell.2014.02.008","volume":"156","author":"A Lu","year":"2014","unstructured":"Lu, A. et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 156, 1193\u20131206 (2014).","journal-title":"Cell"},{"key":"444_CR38","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cell.2014.01.063","volume":"156","author":"X Cai","year":"2014","unstructured":"Cai, X. et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell 156, 1207\u20131222 (2014).","journal-title":"Cell"},{"key":"444_CR39","doi-asserted-by":"crossref","first-page":"41732","DOI":"10.1074\/jbc.M112.381228","volume":"287","author":"PR Vajjhala","year":"2012","unstructured":"Vajjhala, P. R., Mirams, R. E. & Hill, J. M. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J. Biol. Chem. 287, 41732\u201341743 (2012).","journal-title":"J. Biol. Chem."},{"key":"444_CR40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/ni.2749","volume":"14","author":"H Hara","year":"2013","unstructured":"Hara, H. et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat. Immunol. 14, 1247\u20131255 (2013).","journal-title":"Nat. Immunol."},{"key":"444_CR41","volume":"8","author":"T Tang","year":"2017","unstructured":"Tang, T. et al. CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat. Commun. 8, 202 (2017).","journal-title":"Nat. Commun."},{"key":"444_CR42","doi-asserted-by":"crossref","first-page":"12077","DOI":"10.1074\/jbc.M117.797126","volume":"292","author":"R Domingo-Fernandez","year":"2017","unstructured":"Domingo-Fernandez, R., Coll, R. C., Kearney, J., Breit, S. & O\u2019Neill, L. A. J. The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1beta transcription and activate the NLRP3 inflammasome. J. Biol. Chem. 292, 12077\u201312087 (2017).","journal-title":"J. Biol. Chem."},{"key":"444_CR43","first-page":"E9371","volume":"115","author":"JP Green","year":"2018","unstructured":"Green, J. P. et al. Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming. Proc. Natl. Acad. Sci. U.S.A. 115, E9371\u2013E9380 (2018).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"444_CR44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1039\/C8SC04084B","volume":"10","author":"SH Park","year":"2019","unstructured":"Park, S. H., Hyun, J. Y. & Shin, I. A lysosomal chloride ion-selective fluorescent probe for biological applications. Chem. Sci. 10, 56\u201366 (2019).","journal-title":"Chem. Sci."},{"key":"444_CR45","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.febslet.2010.01.027","volume":"584","author":"DR Littler","year":"2010","unstructured":"Littler, D. R. et al. The enigma of the CLIC proteins: Ion channels, redox proteins, enzymes, scaffolding proteins? FEBS Lett. 584, 2093\u20132101 (2010).","journal-title":"FEBS Lett."},{"key":"444_CR46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4049\/jimmunol.181.1.17","volume":"181","author":"H Li","year":"2008","unstructured":"Li, H., Willingham, S. B., Ting, J. P. Y. & Re, F. Cutting edge: inflammasome activation by alum and alum\u2019s adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17\u201321 (2008).","journal-title":"J. Immunol."},{"key":"444_CR47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.immuni.2006.02.004","volume":"24","author":"FS Sutterwala","year":"2006","unstructured":"Sutterwala, F. S. et al. Critical role for NALP3\/CIAS1\/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24, 317\u2013327 (2006).","journal-title":"Immunity"},{"key":"444_CR48","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","volume":"122","author":"PG Steg","year":"2010","unstructured":"Steg, P. G. et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122, 2131\u20132141 (2010).","journal-title":"Circulation"},{"key":"444_CR49","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685\u20131695 (2005).","journal-title":"N. Engl. J. Med."},{"key":"444_CR50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCULATIONAHA.117.031678","volume":"137","author":"JW McEvoy","year":"2018","unstructured":"McEvoy, J. W. et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY Randomized Clinical Trial (platelet aggregation with ticagrelor inhibition and fentanyl). Circulation 137, 307\u2013309 (2018).","journal-title":"Circulation"},{"key":"444_CR51","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12504","volume":"7","author":"MJ Daniels","year":"2016","unstructured":"Daniels, M. J. et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer\u2019s disease in rodent models. Nat. Commun. 7, 12504 (2016).","journal-title":"Nat. Commun."},{"key":"444_CR52","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1084\/jem.20100257","volume":"207","author":"P Broz","year":"2010","unstructured":"Broz, P. et al. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J. Exp. Med. 207, 1745\u20131755 (2010).","journal-title":"J. Exp. Med."},{"key":"444_CR53","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2010-08-263111","volume":"117","author":"M Cattaneo","year":"2011","unstructured":"Cattaneo, M. The platelet P2Y(1)(2) receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117, 2102\u20132112 (2011).","journal-title":"Blood"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0444-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0444-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0444-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:10:56Z","timestamp":1723461056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0444-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1038\/s41423-020-0444-5","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"6 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}